Ezetimibe: effective and safe treatment for dyslipidaemia associated with nonalcoholic fatty liver disease
暂无分享，去创建一个
[1] Mohamed H. Ahmed. The dilemma of invasive and non-invasive investigations for adult and paediatric non-alcoholic fatty liver disease: has the time come for a new biochemical marker? , 2006, Clinical chemistry and laboratory medicine.
[2] C. Byrne,et al. Non‐alcoholic Steatohepatitis , 2005 .
[3] Y. Ioannou,et al. Inactivation of NPC1L1 Causes Multiple Lipid Transport Defects and Protects against Diet-induced Hypercholesterolemia* , 2005, Journal of Biological Chemistry.
[4] M. Davidson,et al. Simvastatin plus ezetimibe: combination therapy for the management of dyslipidaemia , 2005, Expert opinion on pharmacotherapy.
[5] L. Simons,et al. Effects of ezetimibe added to on-going statin therapy on the lipid profile of hypercholesterolemic patients with diabetes mellitus or metabolic syndrome , 2004, Current medical research and opinion.
[6] Luquan Wang,et al. Materials and Methods Figs. S1 to S4 Tables S1 and S2 References Niemann-pick C1 like 1 Protein Is Critical for Intestinal Cholesterol Absorption , 2022 .
[7] R. Suresh,et al. EVALUATION OF THE EFFICACY, SAFETY, AND TOLERABILITY OF EZETIMIBE IN PRIMARY HYPERCHOLESTEROLAEMIA: A POOLED ANALYSIS FROM TWO CONTROLLED PHASE III CLINICAL STUDIES , 2003, International journal of clinical practice.